Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) Major Shareholder Philip R. Harper Buys 20,470 Shares
Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) major shareholder Philip R. Harper bought 20,470 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were purchased at an average price of $1.19 per share, with a total value of $24,359.30. Following the transaction, the insider now owns 4,865,683 shares of the company’s stock, valued at $5,790,162.77. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Aevi Genomic Medicine, Inc. (GNMX) traded up 5.70% during midday trading on Monday, reaching $1.39. The company had a trading volume of 298,133 shares. Aevi Genomic Medicine, Inc. has a 12-month low of $0.98 and a 12-month high of $6.89. The stock has a 50-day moving average price of $1.28 and a 200 day moving average price of $2.40. The company’s market capitalization is $51.58 million.
Hedge funds have recently modified their holdings of the stock. Teachers Advisors LLC purchased a new stake in shares of Aevi Genomic Medicine during the fourth quarter worth approximately $204,000. State Street Corp raised its stake in shares of Aevi Genomic Medicine by 15.4% in the fourth quarter. State Street Corp now owns 345,698 shares of the biotechnology company’s stock worth $1,789,000 after buying an additional 46,149 shares during the last quarter. Northern Capital Management LLC raised its stake in shares of Aevi Genomic Medicine by 317.9% in the second quarter. Northern Capital Management LLC now owns 106,050 shares of the biotechnology company’s stock worth $141,000 after buying an additional 80,675 shares during the last quarter. Birchview Capital LP raised its stake in shares of Aevi Genomic Medicine by 88.2% in the second quarter. Birchview Capital LP now owns 128,000 shares of the biotechnology company’s stock worth $170,000 after buying an additional 60,000 shares during the last quarter. Finally, LMR Partners LLP purchased a new stake in shares of Aevi Genomic Medicine during the second quarter worth approximately $149,000. 27.96% of the stock is owned by institutional investors and hedge funds.
GNMX has been the subject of a number of recent analyst reports. UBS AG reiterated a “positive” rating on shares of Aevi Genomic Medicine in a report on Wednesday, May 10th. Jefferies Group LLC reiterated a “hold” rating and issued a $1.50 price objective on shares of Aevi Genomic Medicine in a report on Monday, August 7th. Finally, ValuEngine downgraded Aevi Genomic Medicine from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.
About Aevi Genomic Medicine
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease.
Receive News & Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.